ライフサイエンスコーパス: pancreas transplant

1 ving related kidney transplant followed by a pancreas transplant.

2 safely in patients who have lost their first pancreas transplant.

3 on dialysis, and 1 had a combined kidney and pancreas transplant.

4 ignificant morbidity after kidney and kidney-pancreas transplant.

5 y-pancreas transplant, 53% received a kidney-pancreas transplant.

6 ver, 12 single and 14 bilateral lung, and 12 pancreas transplants.

7 TFs remain significant after pancreas transplants.

8 transplants, most liver transplants, and all pancreas transplants.

9 nd a high rate of graft survival in solitary pancreas transplants.

10 e from the time of the kidney as well as the pancreas transplants.

11 ssociated with the increased success rate of pancreas transplants.

12 studied 240 recipients of liver, kidney, or pancreas transplants.

13 ecrease in the surgical risk associated with pancreas transplants.

14 e of graft failure in technically successful pancreas transplants.

15 ansplants, and two were recipients of kidney-pancreas transplants.

16 combined kidney/pancreas transplants and 13 pancreas transplants.

17 15, for studies reporting the outcome of DCD pancreas transplants.

18 1518), and 11 to 33 (n = 1377) for solitary pancreas transplants.

19 ge in the interpretation of outcome data for pancreas transplants.

20 ecipient survival for recipients of solitary pancreas transplants.

21 CI, 0.62-2.78; P = 0.47) between DCD and DBD pancreas transplants.

22 ive recipients of seropositive kidney and/or pancreas transplants.

23 March 31, 2000, the authors performed 1,194 pancreas transplants (111 from living donors; 191 retran

24 ncreas-kidney transplant, 79,198 life-years; pancreas transplant, 14,903 life-years; and intestine tr

25 We performed a total 28 pancreas transplants (17 simultaneous kidney-pancreas tr

26 occurred in 41 patients with bladder-drained pancreas transplants (25 SPK, 14 pancrease after kidney

27 Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 2

28 Retrospective analysis of 509 consecutive pancreas transplants (442 simultaneous pancreas and kidn

29 Among those who were waitlisted for a kidney-pancreas transplant, 53% received a kidney-pancreas tran

30 in 441 consecutive cadaver, bladder-drained pancreas transplants (54% simultaneous pancreas and kidn

31 Of those who received a kidney-pancreas transplant, 87% patients underwent SPKT and 13%

32 a 27-year-old female who underwent cadaveric pancreas transplant 9 months after a successful live don

33 pients with enteric-drained or duct-injected pancreas transplants, a laparoscopic or open biopsy shou

34 20 pancreas transplanted alone [PTA], and 47 pancreas transplanted after kidney [PAK]), performed at

35 ter than pancreas after kidney transplant or pancreas transplant alone (11.2 vs. 2.5 years).

36 1), pancreas after kidney (PAK) (n=389), and pancreas transplant alone (PTA) (n=204).

37 7), pancreas after kidney (PAK) (n=399), and pancreas transplant alone (PTA) (n=211).

38 Solitary pancreas transplants, both pancreas transplant alone (PTA) and pancreas after kidne

39 Pancreas transplant alone (PTA) has become accepted ther

40 Recipients of a pancreas transplant alone (PTA) have varying levels of k

41 Recipients of a pancreas transplant alone (PTA) have varying levels of k

42 A pancreas transplant alone (PTA) in a nonuremic patient w

43 ts with end-stage renal disease, the role of pancreas transplant alone (PTA) in the therapy of T1D su

44 Pancreas transplant alone (PTA) is a controversial proce

45 Results were compared with outcomes in pancreas transplant alone (PTA) recipients reported to t

46 pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA).

47 idney (SPK), pancreas after kidney (PAK) and pancreas transplant alone (PTA).

48 as after kidney transplantation [PAK], and 6 pancreas transplant alone [PTA]) between November 2006 a

49 ease after kidney transplants [PAK], amd two pancreas transplant alone [PTA]).

50 [SPK]; 22% pancreas after kidney [PAK]; 24% pancreas transplant alone [PTA]; 37% retransplant).

51 eas-kidney (SPK) and 4308 solitary pancreas (pancreas transplant alone and pancreas after kidney) tra

52 is indication may be about to match those of pancreas transplant alone in insulin independence.

53 Pancreas transplant alone is utilized rarely in diabetic

54 ic drainage, particularly in patients with a pancreas transplant alone or a pancreas after kidney tra

55 ation in native kidneys and urinary tract of pancreas transplant alone patients is not uncommon.

56 pancreas-kidney, pancreas after kidney, and pancreas transplant alone recipients was 2.5%, 1.2%, and

57 PKs over pancreas after kidney transplant or pancreas transplant alone to limit the loss of precious

58 Thirty-eight recipients of pancreas transplant alone were evaluated for evidence of

59 nt, 42% pancreas after kidney transplant, 8% pancreas transplant alone) were biopsied.

60 idence interval [CI], 0.98-2.53; P =.06) for pancreas transplant alone, 1.42 (95% CI, 1.03-1.94; P =.

61 underwent simultaneous kidney and pancreas, pancreas transplant alone, and pancreas after kidney bet

62 year survival rates were 96.5% and 85.2% for pancreas transplant alone, respectively, and 95.3% and 8

63 on the waiting list were 97.6% and 92.1% for pancreas transplant alone, respectively, and 97.1% and 8

64 reas kidney transplantation, and the third a pancreas transplant alone.

65 2 simultaneous pancreas and kidney [SPK], 20 pancreas transplanted alone [PTA], and 47 pancreas trans

66 had SPK transplants without BM, 14 (17%) had pancreas transplants alone (PTA), and 7 (9%) had pancrea

67 reas after kidney (PAK) transplants; and 291 pancreas transplants alone (PTA).

68 Only sequential kidney and pancreas or pancreas transplants alone from live donors had been don

69 pancreas-after-kidney transplants and seven pancreas transplants alone were performed without consid

70 , 13 pancreas after kidney transplants and 4 pancreas transplants alone were performed.

71 n type I patients and did not differ between pancreas transplant and control groups.

72 eatinine levels>1.5 mg/dl at the time of the pancreas transplant and recipient age<30 years.

73 There were 45 combined kidney/pancreas transplants and 13 pancreas transplants.

74 of gene expression with clinical outcome of pancreas transplants and justifies further studies in an

75 kidney transplant, one a simultaneous kidney-pancreas transplant, and the third a living related kidn

76 nce, waitlisted for kidney-alone (vs. kidney-pancreas) transplant, and higher body mass index (longer

77 ategories, and outcomes of patients having a pancreas transplant are discussed, particularly with ref

78 We conclude that successful pancreas transplants are efficacious for periods as long

79 t al. on the BB rat model suggest that whole pancreas transplants are not susceptible to recurrent au

80 Whole and segmental pancreas transplants are now successful for up to two de

81 Pancreas transplants are rarely done in type 2 (noninsul

82 s of 1014 patients undergoing deceased donor pancreas transplant at a single center.

83 factors, and outcomes of CMV infection after pancreas transplant at our center from January 1, 1998,

84 ther a living, cadaveric, or combined kidney-pancreas transplant at our center, and four cases of all

85 (53 men, 29 women) with bladder-drained (BD) pancreas transplants, at 1 to 80 (median, 14) months aft

86 nts at our center who received kidney and/or pancreas transplants between January 2000 and April 2003

87 Data from 232 percutaneous US-guided pancreas transplant biopsies performed in 88 patients we

88 We retrospectively reviewed all laparoscopic pancreas transplant biopsies performed over a 15-month p

89 individual renal transplant biopsies and 19 pancreas transplant biopsies were assayed for expression

90 Pancreas transplant biopsies were taken within approxima

91 Laparoscopic pancreas transplant biopsy allows safe visualization of

92 pancreas-specific genes were evaluated in 26 pancreas transplant biopsy specimens by quantitative rea

93 rmed a pilot feasibility study of mRNA-based pancreas transplant biopsy stratification.

94 Solitary pancreas transplants, both pancreas transplant alone (PT

95 ne (DD KA), not because of the addition of a pancreas transplant but because of differences in organ

96 A in patients undergoing simultaneous kidney-pancreas transplant by evaluating the functional recover

97 While pancreas transplant can be complicated by early graft lo

98 lants for suitable candidates, but currently pancreas transplants can be applied and should be an opt

99 are, unless accepted for a local whole organ pancreas transplant candidate, preferentially allocated

100 rofiles in type 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate

101 ymptomatic type 1 and 2 DM kidney and kidney-pancreas transplant candidates.

102 the transplant patient registry of a kidney-pancreas transplant center between 1984 and 2012.

103 /United Network for Organ Sharing Kidney and Pancreas Transplant Committee retrospectively analyzed t

104 We hypothesized that solitary pancreas transplants could be performed successfully eve

105 the United Network for Organ Sharing kidney/pancreas transplant database investigates factors at the

106 er KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22).

107 comes of primary versus retransplant for all pancreas transplants done in our program over nearly 35

108 We genotyped 435 pancreas transplant donors and 431 recipients who had un

109 We studied the outcome of 225 solitary pancreas transplants during three immunosuppressive eras

110 US findings, are associated with subsequent pancreas transplant failure.

111 The timing of the pancreas transplant for PAK recipients does not seem to

112 diabetic complications requiring whole organ pancreas transplant for salvage.

113 Eventually, islet transplants will replace pancreas transplants for suitable candidates, but curren

114 Here, CEUS studies are extended to pancreas transplants for the first time.

115 mpatible, five HLA antigen-mismatched kidney-pancreas transplant from a 17-year-old African-American

116 ansplantation Network Registry on kidney and pancreas transplants from January 1988 to December 1996,

117 Sequential kidney and pancreas transplants from LDs have been done, but until

118 Previously, we demonstrated that pancreas transplants from the diabetes resistant BB rat

119 results improve and as isolated (PAK or PTA) pancreas transplants gain in popularity, CR will become

120 Host factors (age at pancreas transplant, gender, body weight, glomerular fil

121 subjects receiving either a kidney or kidney-pancreas transplant generally have indicated no differen

122 The mean pancreas transplant graft and patient survival rates for

123 The data were compared between normal pancreas transplants, grafts undergoing rejection, and g

124 Since the 1980s, pancreas transplant has become the most effective treatm

125 al venous drainage, especially with solitary pancreas transplants, has yet to be determined.

126 Numbers of pancreas transplants have been decreasing over the past

127 Traditionally, solitary pancreas transplants have been performed using systemic

128 As of December 31, 1996, a total of 9012 pancreas transplants have been reported to the Internati

129 Compared with other abdominal transplants, pancreas transplants have historically had the highest i

130 re instances with complete thrombosis of the pancreas transplant in absence of clinical manifestation

131 slet mass comparable with whole or segmental pancreas transplants in type 1 diabetic patients can res

132 ow-risk DCD pancreases, as the number of DCD pancreas transplants increase and the threshold for reje

133 Living donor pancreas transplant is a potential treatment for diabeti

134 Pancreas transplant is most commonly performed along wit

135 ncreas after kidney transplant, in which the pancreas transplant is performed some years after renal

136 e kidney transplant before proceeding with a pancreas transplant is unclear.

137 t of isolated splenic vein thrombosis in the pancreas transplant is unknown.

138 f graft failure after technically successful pancreas transplants is rejection.

139 erature on the behavior of cystic lesions in pancreas transplants is scarce, and hence a better under

140 One approach to increase the number of pancreas transplants is to share organs between procurem

141 PALK, n=389), preemptive LDK not receiving a pancreas transplant (LDK/noP, n=289), preemptive DDK (n=

142 Living donor segmental pancreas transplants (LDSPTx) have been performed select

143 For solitary pancreas transplants, low, but not medium, center volume

144 All pancreas transplants (n=124) performed in the previous 3

145 A total of 151 pancreas transplant needle biopsy specimens from 57 pati

146 We conclude that the beneficial effect of a pancreas transplant on the prevalence and severity of hy

147 ultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney

148 ificantly higher in patients with concurrent pancreas transplants or who were hospitalized with docum

149 ificantly higher in patients with concurrent pancreas transplants or who were hospitalized with docum

150 useful models for reporting program-specific pancreas transplant outcomes.

151 n alone followed by a solitary cadaver-donor pancreas transplant (PAK) have been the transplant optio

152 ng donor kidney followed by a deceased donor pancreas transplant (pancreas after living donor kidney

153 were observed most commonly in kidney and/or pancreas transplant patients (26%), although they were a

154 Pancreas transplant patients are free of exogenous insul

155 ntly greater in healthy control subjects and pancreas transplant patients compared with type I subjec

156 Data from 266 pancreas transplant patients including 182 simultaneous

157 We conclude that HCV infection in kidney-pancreas transplant patients results in a significantly

158 kidney retransplants in simultaneous kidney-pancreas transplant patients who lost their first kidney

159 diagnosed (34 kidney, 14 liver, and 3 kidney-pancreas transplant patients).

160 this study of 263 heart, kidney, liver, and pancreas transplant patients, BK virus (BKV) and JC viru

161 more precisely modulate immunosuppression in pancreas transplant patients.

162 responses to hypoglycemia were normalized in pancreas transplant patients.

163 F for nonsensitized primary kidney or kidney/pancreas transplant patients.

164 nd high-dose insulin infusions were lower in pancreas-transplant patients compared with healthy subje

165 In the postabsorptive state, pancreas-transplant patients had similar plasma glucose

166 During hyperinsulinemia, pancreas-transplant patients show a normal inhibition of

167 During insulin infusion, pancreas-transplant patients showed a greater inhibition

168 /- 90 to 187 +/- 25 micromol/l; P < 0.01 vs. pancreas-transplant patients).

169 We assessed risk factors for TF in 1115 pancreas transplants performed at a single center betwee

170 This was a retrospective review of 345 pancreas transplants performed at a single center betwee

171 uthors retrospectively analyzed all solitary pancreas transplants performed at the Mayo Clinic betwee

172 We retrospectively analyzed all cadaver pancreas transplants performed at the University of Minn

173 we reviewed the posttransplant course of all pancreas transplants performed between July 1, 2002 and

174 my, thrombosis, infections, leaks) after 580 pancreas transplants performed during a 12-year period.

175 ective, single-center analysis including all pancreas transplants performed over 9 years evaluating t

176 een problematic as there are three different pancreas transplant procedures that may have different o

177 Monitoring graft survival for pancreas transplant programs has been problematic as the

178 mpared early pancreas graft outcomes at four pancreas transplant programs within the state of Michiga

179 rehensively studied after all three types of pancreas transplant (PT) including simultaneous pancreas

180 For recipients of solitary pancreas transplants (PTA and PAK), we found no differen

181 h acute antibody-mediated rejection (AMR) in pancreas transplant (PTx) is not well defined.

182 ive recipients of seropositive kidney and/or pancreas transplants received valganciclovir prophylaxis

183 ic syndrome (TTP/HUS) developing in a kidney/pancreas transplant recipient after the initiation of tr

184 Pancreas transplant recipient obesity has been associate

185 amined hypoglycemic counterregulation in any pancreas transplant recipient of more than 6 years' dura

186 hropathy in the native kidneys of a solitary-pancreas transplant recipient.

187 of the renal allograft in a combined kidney/pancreas transplant recipient.

188 This study details 11 pancreas transplant recipients (10 combined kidney and p

189 f 88 pancreas transplants were performed; 20 pancreas transplant recipients (23%) developed grade II

190 Thirteen pancreas transplant recipients and matched control subje

191 ly reported cases of WNV infection in kidney/pancreas transplant recipients and the general populatio

192 rent antibody induction regimens in solitary pancreas transplant recipients and to assess the role of

193 Solitary pancreas transplant recipients between 01/98 to 02/00 (n

194 Kidney-pancreas transplant recipients can be safely switched to

195 om normal donor kidneys of successful kidney-pancreas transplant recipients during cyclosporine (CSA)

196 5) Do successful pancreas transplant recipients evince time-dependent dec

197 transplantation remains stable in successful pancreas transplant recipients for up to 19 years after

198 prospectively screened 609 kidney or kidney-pancreas transplant recipients from January 2007 to June

199 However, outcome after pregnancy in pancreas transplant recipients has not been studied in d

200 The long-term outcome of simultaneous kidney pancreas transplant recipients is not well established.

201 oid withdrawal can be safely accomplished in pancreas transplant recipients maintained on tacrolimus-

202 ew three cases of enterocutaneous fistula in pancreas transplant recipients managed nonoperatively wi

203 Group 2A consisted of seven successful pancreas transplant recipients of 5 to 11 years' duratio

204 ains a concern in seronegative kidney and/or pancreas transplant recipients of seropositive organs de

205 Thirty-six pancreas transplant recipients received an induction pro

206 ween August 2003 and May 2006, a total of 97 pancreas transplant recipients received steroid-free mai

207 We have analyzed data from all pancreas transplant recipients reported in the Scientifi

208 The results of steroid withdrawal in pancreas transplant recipients under tacrolimus immunosu

209 ty nondiabetic kidney and 30 diabetic kidney-pancreas transplant recipients underwent 24-hr Holter mo

210 ses and symptom recognition in two groups of pancreas transplant recipients using a stepped hypoglyce

211 However, epinephrine response in pancreas transplant recipients was significantly less th

212 nal allograft rejection in kidney and kidney-pancreas transplant recipients was treated with huOKT3ga

213 creening at our center; 785 kidney or kidney-pancreas transplant recipients were included in our stud

214 A case series of 31 cadaveric pancreas transplant recipients who were insulin-independ

215 retrospective cohort analysis of 137 kidney-pancreas transplant recipients who were transplanted bet

216 We compared the outcomes of pancreas transplant recipients with body mass index (BMI

217 he two most common techniques, CB and PB, in pancreas transplant recipients with presumed rejection.

218 d follow-up biopsies of 20 kidney and kidney-pancreas transplant recipients with PVAN during a time p

219 ucose production (HGP) in 10 type I diabetic pancreas transplant recipients, 10 pair-matched healthy

220 rous rejection episodes in kidney and kidney-pancreas transplant recipients, and in comparison to mur

221 transplantation, from 20 simultaneous kidney-pancreas transplant recipients, randomized to receive ei

222 ients, five kidney transplant and two kidney-pancreas transplant recipients, were treated with the mo

223 ee maintenance immunosuppressive protocol in pancreas transplant recipients.

224 This drug combination was evaluated in pancreas transplant recipients.

225 e unusual cases of intestinal obstruction in pancreas transplant recipients.

226 acute rejection have become less common for pancreas transplant recipients.

227 ejection rate in high-risk kidney and kidney-pancreas transplant recipients.

228 7, both MMF and tacrolimus were given to 120 pancreas transplant recipients.

229 recipients, and 18 were combined kidney and pancreas transplant recipients.

230 tive viremia, from 211 kidney and 141 kidney-pancreas transplant recipients.

231 In conclusion, fasting HGP is increased in pancreas transplant recipients.

232 A antibody monitoring in the surveillance of pancreas transplant recipients.

233 uoia ultrasound machine were evaluated in 14 pancreas transplant recipients.

234 f fasting plasma glucose (FPG) maintained in pancreas transplant recipients?

235 5 heart-transplant recipients, 5 kidney and pancreas-transplant recipients, and 2 lung-transplant re

236 ants have been reported to the International Pancreas Transplant Registry (IPTR).

237 nts, using the database of the International Pancreas Transplant Registry.

238 Chronic pancreas transplant rejection with enteric exocrine drai

239 reduced exposures to cyclosporine to prevent pancreas-transplant rejection.

240 The two solitary pancreas transplants required an operating time of 3 and

241 5.7+/-4 days and 9.5+/-8 days for kidney and pancreas transplants, respectively.

242 As short-term pancreas transplant results improve and as isolated (PAK

243 If PB fails, recipients with bladder-drained pancreas transplants should undergo CB.

244 rt an experience with 71 simultaneous kidney-pancreas transplant (SKPT) recipients receiving daclizum

245 nosuppressive regimen in simultaneous kidney-pancreas transplant (SKPT) recipients.

246 ive agents may allow simultaneous kidney and pancreas transplants (SKPT) to be performed without anti

247 ney transplant (KTx) and simultaneous kidney-pancreas transplant (SPK) recipients, and identified ris

248 tion of kidney (KTx) and simultaneous kidney-pancreas transplant (SPK) recipients.

249 ion in recipients of simultaneous kidney and pancreas transplant (SPK).

250 tom recognition was significantly greater in pancreas transplant subjects than type I patients and di

251 surgery were redefined, and new criteria for pancreas transplant surgery training were developed.

252 Recent improvement in solitary pancreas transplant survival rates has narrowed the adva

253 For isolated pancreas transplants, TF is second only to rejection as

254 d the indication for the biopsy, the type of pancreas transplant, the number of needle passes, the si

255 At 36 months, for all pancreas transplants, the rejection rate was 21% for PV

256 c patients receiving either kidney or kidney-pancreas transplants, the slopes of regression lines gen

257 For solitary pancreas transplants, this option historically provided

258 nated 54 consecutive simultaneous kidney and pancreas transplants to either SE (n = 27) or PE (n = 27

259 The magnitude of the epinephrine response in pancreas transplant type I patients did not correlate wi

260 We first built a predictive model for each pancreas transplant type, and then pooled the transplant

261 Transplant rates for all pancreas transplant types reached a low in 2011 of 34.9

262 The National Pancreas Transplant Unit (NPTU) in Sydney provides a ser

263 1 diabetics enrolled on the renal and renal-pancreas transplant waiting list between 10/01/88 and 06

264 The number of new candidates on the pancreas transplant waiting list has decreased steadily

265 ransplantation alone, but the benefit of the pancreas transplant was evident only in bladder-drained

266 ved kidney function and receiving a solitary pancreas transplant was significantly worse compared wit

267 hepatic insulin sensitivity in recipients of pancreas transplants, we devised a staged euglycemic hyp

268 sure undergoing their first kidney or kidney-pancreas transplant were randomized to calcium, calcium

269 y and one recipient of a combined kidney and pancreas transplant were treated at our center for WNV i

270 Living donor segmental pancreas transplants were associated with higher technic

271 Between 1994 and 2003, 937 pancreas transplants were performed at our center in the

272 y 1994 and March 1998, during which time 137 pancreas transplants were performed at our center using

273 Two thousand one hundred forty-five pancreas transplants were performed at our institution b

274 h December 2002, 787 pancreas and 569 kidney-pancreas transplants were performed at our institution.

275 Four hundred thirty-three pancreas transplants were performed at the Oxford Transp

276 A total of 65 pancreas transplants were performed between July 1, 2002

277 Sixty-two pancreas transplants were performed in 61 patients, of w

278 A total of 914 cadaver pancreas transplants were performed in the following thr

279 Between January 2006 and December 2010, 1009 pancreas transplants were performed in the United Kingdo

280 From July 1994 to January 1999, 177 pancreas transplants were performed, 151 of which were s

281 Between October 2002 and August 2003, 20 pancreas transplants were performed.

282 A total of 88 pancreas transplants were performed; 20 pancreas transpl

283 Six hundred forty solid organ pancreas transplants were performed; 238 had some form o

284 All pancreas transplants were preserved in UW solution.

285 Three of those four pancreas transplants were subsequently lost.

286 chnical failure (TF) rates remain high after pancreas transplants; while rates have decreased over th

287 tient with renal failure receiving MMF for a pancreas transplant, who presented with signs of MMF tox

288 a cadaveric combined kidney-bladder-drained pancreas transplant with a duodenocystostomy for exocrin

289 30 SPLK procedures, coordinating the cadaver pancreas transplant with simultaneous transplantation of

290 of cases, our results suggest that solitary pancreas transplants with a poor HLA match can be perfor

291 Since August 1995, 280 pancreas transplants with enteric duct drainage were ana

292 des improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesi

293 sulin independence must be achieved--as with pancreas transplants--with a single donor.

294 US-guided biopsy of pancreas transplants yielded tissue that was adequate mo